{"transactions":[{"id":845618,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants","published_at":"2026-03-12T20:15:04.000Z","date":"2026-03-10","kind":"purchase","planned":false,"acquired":true,"shares":242945,"price":11.109,"value":2698876.005,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":242945,"derivative":{"exercise_price":0.001,"underlying":"Common Stock","underlying_shares":242945},"source":{"system":"sec-edgar","filing":"0001193125-26-104714","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000119312526104714/ownership.xml","form_type":"4"}},{"id":845617,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-03-12T20:15:04.000Z","date":"2026-03-10","kind":"purchase","planned":false,"acquired":true,"shares":207100,"price":11.11,"value":2300881.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":1297893,"source":{"system":"sec-edgar","filing":"0001193125-26-104714","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000119312526104714/ownership.xml","form_type":"4"}},{"id":904746,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"3.5-Year Common Stock Warrant","published_at":"2026-02-13T16:30:11.000Z","date":"2025-04-17","kind":"other","planned":false,"acquired":false,"shares":1851852,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 16 securities in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":1.37,"exercise_date":"2021-10-18","expiration_date":"2025-04-18","underlying":"Common Stock","underlying_shares":1851852},"source":{"system":"sec-edgar","filing":"0001193125-26-051520","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000119312526051520/ownership.xml","form_type":"5"}},{"id":904745,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-13T16:30:11.000Z","date":"2025-04-17","kind":"other","planned":false,"acquired":true,"shares":1851852,"price":1.37,"value":2537037.24,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 16 securities in which the Reporting Person has no pecuniary interest."}],"balance_after":12273280,"source":{"system":"sec-edgar","filing":"0001193125-26-051520","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000119312526051520/ownership.xml","form_type":"5"}},{"id":909571,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-02-11T16:30:04.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":402273,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Exchange Act or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":402273},"source":{"system":"sec-edgar","filing":"0001193125-26-046662","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000119312526046662/ownership.xml","form_type":"4"}},{"id":909570,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2026-02-11T16:30:04.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":954990,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Exchange Act or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":954990},"source":{"system":"sec-edgar","filing":"0001193125-26-046662","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000119312526046662/ownership.xml","form_type":"4"}},{"id":909569,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2026-02-11T16:30:04.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":737962,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":737962},"source":{"system":"sec-edgar","filing":"0001193125-26-046662","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000119312526046662/ownership.xml","form_type":"4"}},{"id":909568,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-2 Preferred Stock","published_at":"2026-02-11T16:30:04.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1370168},"source":{"system":"sec-edgar","filing":"0001193125-26-046662","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000119312526046662/ownership.xml","form_type":"4"}},{"id":909567,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-1 Preferred Stock","published_at":"2026-02-11T16:30:04.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1370168},"source":{"system":"sec-edgar","filing":"0001193125-26-046662","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000119312526046662/ownership.xml","form_type":"4"}},{"id":909566,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-02-11T16:30:04.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":1619240,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1619240},"source":{"system":"sec-edgar","filing":"0001193125-26-046662","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000119312526046662/ownership.xml","form_type":"4"}},{"id":909565,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T16:30:04.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":402273,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Exchange Act or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":1357263,"source":{"system":"sec-edgar","filing":"0001193125-26-046662","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000119312526046662/ownership.xml","form_type":"4"}},{"id":909564,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T16:30:04.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":954990,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Exchange Act or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":954990,"source":{"system":"sec-edgar","filing":"0001193125-26-046662","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000119312526046662/ownership.xml","form_type":"4"}},{"id":909563,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T16:30:04.000Z","date":"2026-02-09","kind":"purchase","planned":false,"acquired":true,"shares":937500,"price":16,"value":15000000.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":6035038,"source":{"system":"sec-edgar","filing":"0001193125-26-046662","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000119312526046662/ownership.xml","form_type":"4"}},{"id":909562,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T16:30:04.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":737962,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":5097538,"source":{"system":"sec-edgar","filing":"0001193125-26-046662","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000119312526046662/ownership.xml","form_type":"4"}},{"id":909561,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T16:30:04.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":4359576,"source":{"system":"sec-edgar","filing":"0001193125-26-046662","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000119312526046662/ownership.xml","form_type":"4"}},{"id":909560,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T16:30:04.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":2989408,"source":{"system":"sec-edgar","filing":"0001193125-26-046662","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000119312526046662/ownership.xml","form_type":"4"}},{"id":909559,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T16:30:04.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":1619240,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":1619240,"source":{"system":"sec-edgar","filing":"0001193125-26-046662","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000119312526046662/ownership.xml","form_type":"4"}},{"id":1023139,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Perpetual Preferred Stock","published_at":"2025-10-06T21:53:09.000Z","date":"2025-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":100000,"ownership":{"direct":false,"nature":"See Note 5"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F10","text":"The Series B Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $1.4169 per share) as of the conversion date, subject to anti-dilution adjustments. The Series B Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series B Preferred Stock upon the occurrence of certain conditions."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Agreement and Plan of Merger, dated as of December 23, 2024, by and among the Issuer, NH Holdings 2025, Inc. (\"Parent\") and NH Holdings Acquisition 2025, Inc. (\"Merger Sub\"), on October 2, 2025, Merger Sub merged with and into the Issuer with the Issuer surviving such merger as a wholly owned subsidiary of Parent (the \"Merger\"). Pursuant to rollover agreements entered into between certain of the Reporting Persons and NH Holdings 2025 SPV, L.P. (\"Ultimate Parent\"), Parent and Merger Sub, each share of the Issuer's Common Stock, Series A Convertible Perpetual Preferred Stock (\"Series A Preferred Stock\") and Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") beneficially owned by the Reporting Persons was contributed to Ultimate Parent in exchange for limited partnership interests in Ultimate Parent. Each such share of the Issuer's Common Stock, Series A Preferred Stock and Series B Preferred Stock was then cancelled and ceased to exist."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The Series B Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $1.4169 per share) as of the conversion date, subject to anti-dilution adjustments. The Series B Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series B Preferred Stock upon the occurrence of certain conditions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"The Series B Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $1.4169 per share) as of the conversion date, subject to anti-dilution adjustments. The Series B Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series B Preferred Stock upon the occurrence of certain conditions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1352200},"source":{"system":"sec-edgar","filing":"0001193125-25-232143","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":31,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232143/ownership.xml","form_type":"4"}},{"id":1023138,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Perpetual Preferred Stock","published_at":"2025-10-06T21:53:09.000Z","date":"2025-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":125000,"ownership":{"direct":false,"nature":"See Note 5"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"The Series A Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $4.55 per share) as of the conversion date, subject to anti-dilution adjustments. The Series A Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series A Preferred Stock upon the occurrence of certain conditions."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Agreement and Plan of Merger, dated as of December 23, 2024, by and among the Issuer, NH Holdings 2025, Inc. (\"Parent\") and NH Holdings Acquisition 2025, Inc. (\"Merger Sub\"), on October 2, 2025, Merger Sub merged with and into the Issuer with the Issuer surviving such merger as a wholly owned subsidiary of Parent (the \"Merger\"). Pursuant to rollover agreements entered into between certain of the Reporting Persons and NH Holdings 2025 SPV, L.P. (\"Ultimate Parent\"), Parent and Merger Sub, each share of the Issuer's Common Stock, Series A Convertible Perpetual Preferred Stock (\"Series A Preferred Stock\") and Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") beneficially owned by the Reporting Persons was contributed to Ultimate Parent in exchange for limited partnership interests in Ultimate Parent. Each such share of the Issuer's Common Stock, Series A Preferred Stock and Series B Preferred Stock was then cancelled and ceased to exist."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The Series A Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $4.55 per share) as of the conversion date, subject to anti-dilution adjustments. The Series A Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series A Preferred Stock upon the occurrence of certain conditions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The Series A Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $4.55 per share) as of the conversion date, subject to anti-dilution adjustments. The Series A Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series A Preferred Stock upon the occurrence of certain conditions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":550323},"source":{"system":"sec-edgar","filing":"0001193125-25-232143","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":30,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232143/ownership.xml","form_type":"4"}},{"id":1023137,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-10-06T21:53:09.000Z","date":"2025-10-02","kind":"exercise","planned":false,"acquired":false,"shares":124085,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 5"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The warrants became fully exercisable on October 2, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The warrants became fully exercisable on October 2, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":124085},"source":{"system":"sec-edgar","filing":"0001193125-25-232143","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":29,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232143/ownership.xml","form_type":"4"}},{"id":1023136,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-10-06T21:53:09.000Z","date":"2025-10-02","kind":"grant","planned":false,"acquired":true,"shares":124085,"ownership":{"direct":false,"nature":"See Note 5"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Warrants issued pursuant to the Warrantholders Agreement, dated September 30, 2025 between the Issuer and the holders listed on Schedule 1 thereto, and the Credit Agreement, dated August 4, 2023, as amended by that certain Incremental Amendment No. 1, dated as of October 2, 2023, that certain Incremental Amendment No. 2, dated as of April 8, 2024, that certain Amendment No. 3, dated as of June 21, 2024, that certain Amendment No. 4, dated as of October 29, 2024, and that certain Amendment No. 5, dated as of September 30, 2025, between the Issuer and the lenders thereto."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":124085,"derivative":{"exercise_price":0.01,"exercise_date":"2025-10-02","expiration_date":"2030-10-02","underlying":"Common Stock","underlying_shares":124085},"source":{"system":"sec-edgar","filing":"0001193125-25-232143","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232143/ownership.xml","form_type":"4"}},{"id":1023135,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-10-06T21:53:09.000Z","date":"2025-10-02","kind":"other","planned":false,"acquired":false,"shares":607536,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 5"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The warrants became exercisable as to 371,187 shares on April 30, 2024, 28,399 shares on June 21, 2024, 185,595 shares on October 2, 2024 and 22,355 shares on September 26, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F12","text":"The warrants became exercisable as to 371,187 shares on April 30, 2024, 28,399 shares on June 21, 2024, 185,595 shares on October 2, 2024 and 22,355 shares on September 26, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":607536},"source":{"system":"sec-edgar","filing":"0001193125-25-232143","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232143/ownership.xml","form_type":"4"}},{"id":1023134,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-10-06T21:53:09.000Z","date":"2025-10-02","kind":"other","planned":false,"acquired":false,"shares":1656789,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 5"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The warrants became exercisable as to 828,395 shares on August 29, 2023, 552,263 shares on September 18, 2023, 100,606 shares on November 1, 2023 and 175,525 shares on December 20, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"The warrants became exercisable as to 828,395 shares on August 29, 2023, 552,263 shares on September 18, 2023, 100,606 shares on November 1, 2023 and 175,525 shares on December 20, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":1656789},"source":{"system":"sec-edgar","filing":"0001193125-25-232143","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232143/ownership.xml","form_type":"4"}},{"id":1023133,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Perpetual Preferred Stock","published_at":"2025-10-06T21:53:09.000Z","date":"2025-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":37700,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F10","text":"The Series B Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $1.4169 per share) as of the conversion date, subject to anti-dilution adjustments. The Series B Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series B Preferred Stock upon the occurrence of certain conditions."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Agreement and Plan of Merger, dated as of December 23, 2024, by and among the Issuer, NH Holdings 2025, Inc. (\"Parent\") and NH Holdings Acquisition 2025, Inc. (\"Merger Sub\"), on October 2, 2025, Merger Sub merged with and into the Issuer with the Issuer surviving such merger as a wholly owned subsidiary of Parent (the \"Merger\"). Pursuant to rollover agreements entered into between certain of the Reporting Persons and NH Holdings 2025 SPV, L.P. (\"Ultimate Parent\"), Parent and Merger Sub, each share of the Issuer's Common Stock, Series A Convertible Perpetual Preferred Stock (\"Series A Preferred Stock\") and Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") beneficially owned by the Reporting Persons was contributed to Ultimate Parent in exchange for limited partnership interests in Ultimate Parent. Each such share of the Issuer's Common Stock, Series A Preferred Stock and Series B Preferred Stock was then cancelled and ceased to exist."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The Series B Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $1.4169 per share) as of the conversion date, subject to anti-dilution adjustments. The Series B Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series B Preferred Stock upon the occurrence of certain conditions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"The Series B Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $1.4169 per share) as of the conversion date, subject to anti-dilution adjustments. The Series B Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series B Preferred Stock upon the occurrence of certain conditions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":509780},"source":{"system":"sec-edgar","filing":"0001193125-25-232143","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232143/ownership.xml","form_type":"4"}},{"id":1023132,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Perpetual Preferred Stock","published_at":"2025-10-06T21:53:09.000Z","date":"2025-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":75000,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"The Series A Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $4.55 per share) as of the conversion date, subject to anti-dilution adjustments. The Series A Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series A Preferred Stock upon the occurrence of certain conditions."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Agreement and Plan of Merger, dated as of December 23, 2024, by and among the Issuer, NH Holdings 2025, Inc. (\"Parent\") and NH Holdings Acquisition 2025, Inc. (\"Merger Sub\"), on October 2, 2025, Merger Sub merged with and into the Issuer with the Issuer surviving such merger as a wholly owned subsidiary of Parent (the \"Merger\"). Pursuant to rollover agreements entered into between certain of the Reporting Persons and NH Holdings 2025 SPV, L.P. (\"Ultimate Parent\"), Parent and Merger Sub, each share of the Issuer's Common Stock, Series A Convertible Perpetual Preferred Stock (\"Series A Preferred Stock\") and Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") beneficially owned by the Reporting Persons was contributed to Ultimate Parent in exchange for limited partnership interests in Ultimate Parent. Each such share of the Issuer's Common Stock, Series A Preferred Stock and Series B Preferred Stock was then cancelled and ceased to exist."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The Series A Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $4.55 per share) as of the conversion date, subject to anti-dilution adjustments. The Series A Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series A Preferred Stock upon the occurrence of certain conditions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The Series A Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $4.55 per share) as of the conversion date, subject to anti-dilution adjustments. The Series A Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series A Preferred Stock upon the occurrence of certain conditions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":330194},"source":{"system":"sec-edgar","filing":"0001193125-25-232143","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232143/ownership.xml","form_type":"4"}},{"id":1023131,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-10-06T21:53:09.000Z","date":"2025-10-02","kind":"exercise","planned":false,"acquired":false,"shares":186128,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The warrants became fully exercisable on October 2, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The warrants became fully exercisable on October 2, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":186128},"source":{"system":"sec-edgar","filing":"0001193125-25-232143","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232143/ownership.xml","form_type":"4"}},{"id":1023130,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-10-06T21:53:09.000Z","date":"2025-10-02","kind":"grant","planned":false,"acquired":true,"shares":186128,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Warrants issued pursuant to the Warrantholders Agreement, dated September 30, 2025 between the Issuer and the holders listed on Schedule 1 thereto, and the Credit Agreement, dated August 4, 2023, as amended by that certain Incremental Amendment No. 1, dated as of October 2, 2023, that certain Incremental Amendment No. 2, dated as of April 8, 2024, that certain Amendment No. 3, dated as of June 21, 2024, that certain Amendment No. 4, dated as of October 29, 2024, and that certain Amendment No. 5, dated as of September 30, 2025, between the Issuer and the lenders thereto."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":186128,"derivative":{"exercise_price":0.01,"exercise_date":"2025-10-02","expiration_date":"2030-10-02","underlying":"Common Stock","underlying_shares":186128},"source":{"system":"sec-edgar","filing":"0001193125-25-232143","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232143/ownership.xml","form_type":"4"}},{"id":1023129,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-10-06T21:53:09.000Z","date":"2025-10-02","kind":"other","planned":false,"acquired":false,"shares":189195,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The warrants became exercisable as to 123,729 shares on April 30, 2024, 1,733 shares on June 21, 2024, 61,865 shares on October 2, 2024 and 1,868 shares on September 26, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The warrants became exercisable as to 123,729 shares on April 30, 2024, 1,733 shares on June 21, 2024, 61,865 shares on October 2, 2024 and 1,868 shares on September 26, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":189195},"source":{"system":"sec-edgar","filing":"0001193125-25-232143","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232143/ownership.xml","form_type":"4"}},{"id":1023128,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-10-06T21:53:09.000Z","date":"2025-10-02","kind":"exercise","planned":false,"acquired":false,"shares":372255,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The warrants became fully exercisable on October 2, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The warrants became fully exercisable on October 2, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":372255},"source":{"system":"sec-edgar","filing":"0001193125-25-232143","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232143/ownership.xml","form_type":"4"}},{"id":1023127,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-10-06T21:53:09.000Z","date":"2025-10-02","kind":"grant","planned":false,"acquired":true,"shares":372255,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Warrants issued pursuant to the Warrantholders Agreement, dated September 30, 2025 between the Issuer and the holders listed on Schedule 1 thereto, and the Credit Agreement, dated August 4, 2023, as amended by that certain Incremental Amendment No. 1, dated as of October 2, 2023, that certain Incremental Amendment No. 2, dated as of April 8, 2024, that certain Amendment No. 3, dated as of June 21, 2024, that certain Amendment No. 4, dated as of October 29, 2024, and that certain Amendment No. 5, dated as of September 30, 2025, between the Issuer and the lenders thereto."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":372255,"derivative":{"exercise_price":0.01,"exercise_date":"2025-10-02","expiration_date":"2030-10-02","underlying":"Common Stock","underlying_shares":372255},"source":{"system":"sec-edgar","filing":"0001193125-25-232143","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232143/ownership.xml","form_type":"4"}},{"id":1023126,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-10-06T21:53:09.000Z","date":"2025-10-02","kind":"other","planned":false,"acquired":false,"shares":189195,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The warrants became exercisable as to 123,729 shares on April 30, 2024, 1,733 shares on June 21, 2024, 61,865 shares on October 2, 2024 and 1,868 shares on September 26, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The warrants became exercisable as to 123,729 shares on April 30, 2024, 1,733 shares on June 21, 2024, 61,865 shares on October 2, 2024 and 1,868 shares on September 26, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":189195},"source":{"system":"sec-edgar","filing":"0001193125-25-232143","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232143/ownership.xml","form_type":"4"}},{"id":1023125,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:53:09.000Z","date":"2025-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2384873,"ownership":{"direct":false,"nature":"See Note 5"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Agreement and Plan of Merger, dated as of December 23, 2024, by and among the Issuer, NH Holdings 2025, Inc. (\"Parent\") and NH Holdings Acquisition 2025, Inc. (\"Merger Sub\"), on October 2, 2025, Merger Sub merged with and into the Issuer with the Issuer surviving such merger as a wholly owned subsidiary of Parent (the \"Merger\"). Pursuant to rollover agreements entered into between certain of the Reporting Persons and NH Holdings 2025 SPV, L.P. (\"Ultimate Parent\"), Parent and Merger Sub, each share of the Issuer's Common Stock, Series A Convertible Perpetual Preferred Stock (\"Series A Preferred Stock\") and Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") beneficially owned by the Reporting Persons was contributed to Ultimate Parent in exchange for limited partnership interests in Ultimate Parent. Each such share of the Issuer's Common Stock, Series A Preferred Stock and Series B Preferred Stock was then cancelled and ceased to exist."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-232143","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232143/ownership.xml","form_type":"4"}},{"id":1023124,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:53:09.000Z","date":"2025-10-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":182,"price":6.75,"value":1228.5,"ownership":{"direct":false,"nature":"See Note 5"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the cashless net exercise of a warrant through the surrender of shares to the Issuer based on a fair market value of $6.75 per share, the closing market price of the Issuer's common stock on October 1, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":2384873,"source":{"system":"sec-edgar","filing":"0001193125-25-232143","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232143/ownership.xml","form_type":"4"}},{"id":1023123,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:53:09.000Z","date":"2025-10-02","kind":"exercise","planned":false,"acquired":true,"shares":124085,"price":0.01,"value":1240.85,"ownership":{"direct":false,"nature":"See Note 5"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":2385055,"source":{"system":"sec-edgar","filing":"0001193125-25-232143","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232143/ownership.xml","form_type":"4"}},{"id":1023122,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:53:09.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":900,"price":6.75,"value":6075.0,"ownership":{"direct":false,"nature":"See Note 5"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the cashless net exercise of a warrant through the surrender of shares to the Issuer based on a fair market value of $6.75 per share, the closing market price of the Issuer's common stock on October 1, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":2260970,"source":{"system":"sec-edgar","filing":"0001193125-25-232143","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232143/ownership.xml","form_type":"4"}},{"id":1023121,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:53:09.000Z","date":"2025-10-02","kind":"other","planned":false,"acquired":true,"shares":607536,"price":0.01,"value":6075.36,"ownership":{"direct":false,"nature":"See Note 5"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":2261870,"source":{"system":"sec-edgar","filing":"0001193125-25-232143","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232143/ownership.xml","form_type":"4"}},{"id":1023120,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:53:09.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":2455,"price":6.75,"value":16571.25,"ownership":{"direct":false,"nature":"See Note 5"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the cashless net exercise of a warrant through the surrender of shares to the Issuer based on a fair market value of $6.75 per share, the closing market price of the Issuer's common stock on October 1, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":1654334,"source":{"system":"sec-edgar","filing":"0001193125-25-232143","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232143/ownership.xml","form_type":"4"}},{"id":1023119,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:53:09.000Z","date":"2025-10-02","kind":"other","planned":false,"acquired":true,"shares":1656789,"price":0.01,"value":16567.89,"ownership":{"direct":false,"nature":"See Note 5"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":1656789,"source":{"system":"sec-edgar","filing":"0001193125-25-232143","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232143/ownership.xml","form_type":"4"}},{"id":1023118,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:53:09.000Z","date":"2025-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":674554,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Agreement and Plan of Merger, dated as of December 23, 2024, by and among the Issuer, NH Holdings 2025, Inc. (\"Parent\") and NH Holdings Acquisition 2025, Inc. (\"Merger Sub\"), on October 2, 2025, Merger Sub merged with and into the Issuer with the Issuer surviving such merger as a wholly owned subsidiary of Parent (the \"Merger\"). Pursuant to rollover agreements entered into between certain of the Reporting Persons and NH Holdings 2025 SPV, L.P. (\"Ultimate Parent\"), Parent and Merger Sub, each share of the Issuer's Common Stock, Series A Convertible Perpetual Preferred Stock (\"Series A Preferred Stock\") and Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") beneficially owned by the Reporting Persons was contributed to Ultimate Parent in exchange for limited partnership interests in Ultimate Parent. Each such share of the Issuer's Common Stock, Series A Preferred Stock and Series B Preferred Stock was then cancelled and ceased to exist."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-232143","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232143/ownership.xml","form_type":"4"}},{"id":1023117,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:53:09.000Z","date":"2025-10-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":276,"price":6.75,"value":1863.0,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the cashless net exercise of a warrant through the surrender of shares to the Issuer based on a fair market value of $6.75 per share, the closing market price of the Issuer's common stock on October 1, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":674554,"source":{"system":"sec-edgar","filing":"0001193125-25-232143","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232143/ownership.xml","form_type":"4"}},{"id":1023116,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:53:09.000Z","date":"2025-10-02","kind":"exercise","planned":false,"acquired":true,"shares":186128,"price":0.01,"value":1861.28,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":674830,"source":{"system":"sec-edgar","filing":"0001193125-25-232143","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232143/ownership.xml","form_type":"4"}},{"id":1023115,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:53:09.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":280,"price":6.75,"value":1890.0,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the cashless net exercise of a warrant through the surrender of shares to the Issuer based on a fair market value of $6.75 per share, the closing market price of the Issuer's common stock on October 1, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":488702,"source":{"system":"sec-edgar","filing":"0001193125-25-232143","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232143/ownership.xml","form_type":"4"}},{"id":1023114,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:53:09.000Z","date":"2025-10-02","kind":"other","planned":false,"acquired":true,"shares":189195,"price":0.01,"value":1891.95,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":488982,"source":{"system":"sec-edgar","filing":"0001193125-25-232143","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232143/ownership.xml","form_type":"4"}},{"id":1023113,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:53:09.000Z","date":"2025-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1159683,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Agreement and Plan of Merger, dated as of December 23, 2024, by and among the Issuer, NH Holdings 2025, Inc. (\"Parent\") and NH Holdings Acquisition 2025, Inc. (\"Merger Sub\"), on October 2, 2025, Merger Sub merged with and into the Issuer with the Issuer surviving such merger as a wholly owned subsidiary of Parent (the \"Merger\"). Pursuant to rollover agreements entered into between certain of the Reporting Persons and NH Holdings 2025 SPV, L.P. (\"Ultimate Parent\"), Parent and Merger Sub, each share of the Issuer's Common Stock, Series A Convertible Perpetual Preferred Stock (\"Series A Preferred Stock\") and Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") beneficially owned by the Reporting Persons was contributed to Ultimate Parent in exchange for limited partnership interests in Ultimate Parent. Each such share of the Issuer's Common Stock, Series A Preferred Stock and Series B Preferred Stock was then cancelled and ceased to exist."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-232143","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232143/ownership.xml","form_type":"4"}},{"id":1023112,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:53:09.000Z","date":"2025-10-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":551,"price":6.75,"value":3719.25,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the cashless net exercise of a warrant through the surrender of shares to the Issuer based on a fair market value of $6.75 per share, the closing market price of the Issuer's common stock on October 1, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":1159683,"source":{"system":"sec-edgar","filing":"0001193125-25-232143","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232143/ownership.xml","form_type":"4"}},{"id":1023111,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:53:09.000Z","date":"2025-10-02","kind":"exercise","planned":false,"acquired":true,"shares":372255,"price":0.01,"value":3722.55,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":1160234,"source":{"system":"sec-edgar","filing":"0001193125-25-232143","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232143/ownership.xml","form_type":"4"}},{"id":1023110,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:53:09.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":280,"price":6.75,"value":1890.0,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the cashless net exercise of a warrant through the surrender of shares to the Issuer based on a fair market value of $6.75 per share, the closing market price of the Issuer's common stock on October 1, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":787979,"source":{"system":"sec-edgar","filing":"0001193125-25-232143","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232143/ownership.xml","form_type":"4"}},{"id":1023109,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:53:09.000Z","date":"2025-10-02","kind":"other","planned":false,"acquired":true,"shares":189195,"price":0.01,"value":1891.95,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":788259,"source":{"system":"sec-edgar","filing":"0001193125-25-232143","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232143/ownership.xml","form_type":"4"}},{"id":1147022,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-15T16:28:27.000Z","date":"2025-05-15","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":41000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was cancelled without consideration pursuant to the terms of the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":1.42,"expiration_date":"2034-05-24","underlying":"Common Stock","underlying_shares":41000},"source":{"system":"sec-edgar","filing":"0000950170-25-072714","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000095017025072714/ownership.xml","form_type":"4"}},{"id":1147021,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-15T16:28:27.000Z","date":"2025-05-15","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":86762,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was cancelled without consideration pursuant to the terms of the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":4.81,"expiration_date":"2033-05-25","underlying":"Common Stock","underlying_shares":86762},"source":{"system":"sec-edgar","filing":"0000950170-25-072714","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000095017025072714/ownership.xml","form_type":"4"}},{"id":1147020,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-15T16:28:27.000Z","date":"2025-05-15","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":99590,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was cancelled without consideration pursuant to the terms of the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":2.62,"expiration_date":"2032-05-25","underlying":"Common Stock","underlying_shares":99590},"source":{"system":"sec-edgar","filing":"0000950170-25-072714","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000095017025072714/ownership.xml","form_type":"4"}},{"id":1147019,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-15T16:28:27.000Z","date":"2025-05-15","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was cancelled without consideration pursuant to the terms of the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":99.83,"expiration_date":"2031-05-25","underlying":"Common Stock","underlying_shares":7700},"source":{"system":"sec-edgar","filing":"0000950170-25-072714","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000095017025072714/ownership.xml","form_type":"4"}},{"id":1147018,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-15T16:28:27.000Z","date":"2025-05-15","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was cancelled without consideration pursuant to the terms of the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":72.54,"expiration_date":"2030-05-26","underlying":"Common Stock","underlying_shares":7700},"source":{"system":"sec-edgar","filing":"0000950170-25-072714","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000095017025072714/ownership.xml","form_type":"4"}},{"id":1147017,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-15T16:28:27.000Z","date":"2025-05-15","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was cancelled without consideration pursuant to the terms of the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":40,"expiration_date":"2029-06-06","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0000950170-25-072714","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000095017025072714/ownership.xml","form_type":"4"}},{"id":1147016,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-15T16:28:27.000Z","date":"2025-05-15","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":37600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was cancelled without consideration pursuant to the terms of the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2028-07-06","underlying":"Common Stock","underlying_shares":37600},"source":{"system":"sec-edgar","filing":"0000950170-25-072714","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000095017025072714/ownership.xml","form_type":"4"}},{"id":1147015,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-15T16:28:27.000Z","date":"2025-05-15","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3386400,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to that certain Agreement and Plan of Merger, dated April 1, 2025, by and among the Issuer, Concentra Biosciences, LLC and Concentra Merger Sub III, Inc. (the \"Merger Agreement\") in exchange for $0.33 in cash per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-072714","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000095017025072714/ownership.xml","form_type":"4"}},{"id":1147014,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-15T16:28:27.000Z","date":"2025-05-15","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2760860,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to that certain Agreement and Plan of Merger, dated April 1, 2025, by and among the Issuer, Concentra Biosciences, LLC and Concentra Merger Sub III, Inc. (the \"Merger Agreement\") in exchange for $0.33 in cash per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 16 securities in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-072714","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000095017025072714/ownership.xml","form_type":"4"}},{"id":1323293,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":66498,"kind":"organization","name":"New Enterprise Associates 16, L.P.","position":1,"cik":"0001694560","reported_name":"New Enterprise Associates 16, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":66499,"kind":"organization","name":"NEA Partners 16, L.P.","position":2,"cik":"0001712881","reported_name":"NEA Partners 16, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":66500,"kind":"organization","name":"NEA 16 GP, LLC","position":3,"cik":"0001712882","reported_name":"NEA 16 GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61210,"kind":"person","name":"BASKETT FOREST","position":4,"cik":"0001277631","reported_name":"BASKETT FOREST","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38171,"kind":"person","name":"Chang Carmen","position":5,"cik":"0001746342","reported_name":"Chang Carmen","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":31983,"kind":"person","name":"Behbahani Ali","position":6,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23293,"kind":"person","name":"Florence Anthony A. Jr.","position":7,"cik":"0001559827","reported_name":"Florence Anthony A. Jr.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23295,"kind":"person","name":"Makhzoumi Mohamad","position":8,"cik":"0001630226","reported_name":"Makhzoumi Mohamad","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23294,"kind":"person","name":"SANDELL SCOTT D","position":9,"cik":"0001237289","reported_name":"SANDELL SCOTT D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61190,"kind":"person","name":"Walker Paul Edward","position":10,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-23T21:40:48.000Z","date":"2024-12-23","kind":"purchase","planned":false,"acquired":true,"shares":554250,"price":3.2,"value":1773600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired from the Issuer on December 23, 2024 pursuant to a Securities Purchase Agreement dated December 19, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On January 26, 2023, the Issuer effected a 1-for-10 reverse stock split of its common stock (the \"Reverse Stock Split\"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities are directly held by New Enterprise Associates 16, L.P. (\"NEA 16\"), and indirectly held by NEA Partners 16, L.P. (\"NEA Partners 16\"), the sole general partner of NEA 16, NEA 16 GP, LLC (\"NEA 16 GP\"), the sole general partner of NEA Partners 16, and the individual managers of NEA 16 GP (NEA Partners 16, NEA 16 GP and the individual managers of NEA 16 GP, together, the \"Indirect Reporting Persons\").The individual managers of NEA 16 GP are Forest Baskett, Ali Behbahani, Carmen Chang, Anthony A. Florence, Jr., Mohamad Makhzoumi,  Scott D. Sandell, and Paul Walker. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares of the Issuer held by NEA 16 in which the Indirect Reporting Persons have no pecuniary interest."}],"balance_after":1625678,"source":{"system":"sec-edgar","filing":"0000950170-24-139630","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000095017024139630/ownership.xml","form_type":"4"}},{"id":1392039,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2024-10-03T22:34:49.000Z","date":"2024-10-01","kind":"purchase","planned":false,"acquired":true,"shares":185595,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Warrants issued pursuant to the Warrantholders Agreement, dated April 8, 2024, between the Issuer and the holders listed on Schedule 1 thereto, and the Credit Agreement, dated August 4, 2023, as amended by that certain Incremental Amendment No. 1, dated as of October 2, 2023, and that certain Incremental Amendment No. 2, dated as of April 8, 2024, between the Issuer and the lenders thereto."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":556782,"derivative":{"exercise_price":0.01,"exercise_date":"2024-10-02","expiration_date":"2029-04-30","underlying":"Common Stock","underlying_shares":185595},"source":{"system":"sec-edgar","filing":"0000950170-24-112611","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000095017024112611/ownership.xml","form_type":"4"}},{"id":1392038,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2024-10-03T22:34:49.000Z","date":"2024-10-01","kind":"purchase","planned":false,"acquired":true,"shares":61865,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Warrants issued pursuant to the Warrantholders Agreement, dated April 8, 2024, between the Issuer and the holders listed on Schedule 1 thereto, and the Credit Agreement, dated August 4, 2023, as amended by that certain Incremental Amendment No. 1, dated as of October 2, 2023, and that certain Incremental Amendment No. 2, dated as of April 8, 2024, between the Issuer and the lenders thereto."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":185594,"derivative":{"exercise_price":0.01,"exercise_date":"2024-10-02","expiration_date":"2029-04-30","underlying":"Common Stock","underlying_shares":61865},"source":{"system":"sec-edgar","filing":"0000950170-24-112611","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000095017024112611/ownership.xml","form_type":"4"}},{"id":1392037,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2024-10-03T22:34:49.000Z","date":"2024-10-01","kind":"purchase","planned":false,"acquired":true,"shares":61865,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Warrants issued pursuant to the Warrantholders Agreement, dated April 8, 2024, between the Issuer and the holders listed on Schedule 1 thereto, and the Credit Agreement, dated August 4, 2023, as amended by that certain Incremental Amendment No. 1, dated as of October 2, 2023, and that certain Incremental Amendment No. 2, dated as of April 8, 2024, between the Issuer and the lenders thereto."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":185594,"derivative":{"exercise_price":0.01,"exercise_date":"2024-10-02","expiration_date":"2029-04-30","underlying":"Common Stock","underlying_shares":61865},"source":{"system":"sec-edgar","filing":"0000950170-24-112611","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000095017024112611/ownership.xml","form_type":"4"}},{"id":1405194,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2024-09-18T00:18:53.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":25142840,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2091383},"source":{"system":"sec-edgar","filing":"0000950170-24-107544","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000095017024107544/ownership.xml","form_type":"4"}},{"id":1405193,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-09-18T00:18:53.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":12299854,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1023103},"source":{"system":"sec-edgar","filing":"0000950170-24-107544","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000095017024107544/ownership.xml","form_type":"4"}},{"id":1405192,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-18T00:18:53.000Z","date":"2024-09-16","kind":"purchase","planned":false,"acquired":true,"shares":500000,"price":16,"value":8000000.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":3614486,"source":{"system":"sec-edgar","filing":"0000950170-24-107544","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000095017024107544/ownership.xml","form_type":"4"}},{"id":1405191,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-18T00:18:53.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":true,"shares":2091383,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":3114486,"source":{"system":"sec-edgar","filing":"0000950170-24-107544","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000095017024107544/ownership.xml","form_type":"4"}},{"id":1405190,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-18T00:18:53.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":true,"shares":1023103,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":1023103,"source":{"system":"sec-edgar","filing":"0000950170-24-107544","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000095017024107544/ownership.xml","form_type":"4"}},{"id":1498841,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-29T20:13:23.000Z","date":"2024-05-24","kind":"grant","planned":false,"acquired":true,"shares":41000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 100% of the shares on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual Meeting of stockholders that occurs following the grant, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":41000,"derivative":{"exercise_price":1.42,"expiration_date":"2034-05-24","underlying":"Common Stock","underlying_shares":41000},"source":{"system":"sec-edgar","filing":"0000950170-24-066178","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000095017024066178/ownership.xml","form_type":"4"}},{"id":1536020,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-24T17:00:23.000Z","date":"2024-04-22","kind":"purchase","planned":false,"acquired":true,"shares":17857,"price":56,"value":999992.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired from the Issuer on April 22, 2024 pursuant to a Subscription Agreement dated April 17, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":1090793,"source":{"system":"sec-edgar","filing":"0000950170-24-047683","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000095017024047683/ownership.xml","form_type":"4"}},{"id":1543793,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2024-04-10T23:28:00.000Z","date":"2024-04-08","kind":"purchase","planned":false,"acquired":true,"shares":371187,"ownership":{"direct":false,"nature":"See Note 5"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Warrants to be issued pursuant to the Warrantholders Agreement and the Credit Agreement, dated August 4, 2023, as amended by that certain Incremental Amendment No. 1, dated as of October 2, 2023, and that certain Incremental Amendment No. 2, dated as of April 8, 2024, between the Issuer and the lenders thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Warrantholders Agreement (\"Warrantholders Agreement\"), dated April 8, 2024, between the Issuer and the holders listed on Schedule 1 thereto, the warrants will be issued on the first business day following the conclusion of the 10 calendar day period after the distribution of the letter required to be mailed by the Issuer to its shareholders pursuant to Section 312.05 of the NYSE Listed Company Manual (such date, the \"Closing Date\"). The warrants will be exercisable at any time after issuance and prior to the close of business on the fifth anniversary of the Closing Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Warrantholders Agreement (\"Warrantholders Agreement\"), dated April 8, 2024, between the Issuer and the holders listed on Schedule 1 thereto, the warrants will be issued on the first business day following the conclusion of the 10 calendar day period after the distribution of the letter required to be mailed by the Issuer to its shareholders pursuant to Section 312.05 of the NYSE Listed Company Manual (such date, the \"Closing Date\"). The warrants will be exercisable at any time after issuance and prior to the close of business on the fifth anniversary of the Closing Date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":371187,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":371187},"source":{"system":"sec-edgar","filing":"0000950170-24-043493","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000095017024043493/ownership.xml","form_type":"4"}},{"id":1543792,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2024-04-10T23:28:00.000Z","date":"2024-04-08","kind":"purchase","planned":false,"acquired":true,"shares":123729,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Warrants to be issued pursuant to the Warrantholders Agreement and the Credit Agreement, dated August 4, 2023, as amended by that certain Incremental Amendment No. 1, dated as of October 2, 2023, and that certain Incremental Amendment No. 2, dated as of April 8, 2024, between the Issuer and the lenders thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Warrantholders Agreement (\"Warrantholders Agreement\"), dated April 8, 2024, between the Issuer and the holders listed on Schedule 1 thereto, the warrants will be issued on the first business day following the conclusion of the 10 calendar day period after the distribution of the letter required to be mailed by the Issuer to its shareholders pursuant to Section 312.05 of the NYSE Listed Company Manual (such date, the \"Closing Date\"). The warrants will be exercisable at any time after issuance and prior to the close of business on the fifth anniversary of the Closing Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Warrantholders Agreement (\"Warrantholders Agreement\"), dated April 8, 2024, between the Issuer and the holders listed on Schedule 1 thereto, the warrants will be issued on the first business day following the conclusion of the 10 calendar day period after the distribution of the letter required to be mailed by the Issuer to its shareholders pursuant to Section 312.05 of the NYSE Listed Company Manual (such date, the \"Closing Date\"). The warrants will be exercisable at any time after issuance and prior to the close of business on the fifth anniversary of the Closing Date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":123729,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":123729},"source":{"system":"sec-edgar","filing":"0000950170-24-043493","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000095017024043493/ownership.xml","form_type":"4"}},{"id":1543791,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2024-04-10T23:28:00.000Z","date":"2024-04-08","kind":"purchase","planned":false,"acquired":true,"shares":123729,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Warrants to be issued pursuant to the Warrantholders Agreement and the Credit Agreement, dated August 4, 2023, as amended by that certain Incremental Amendment No. 1, dated as of October 2, 2023, and that certain Incremental Amendment No. 2, dated as of April 8, 2024, between the Issuer and the lenders thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Warrantholders Agreement (\"Warrantholders Agreement\"), dated April 8, 2024, between the Issuer and the holders listed on Schedule 1 thereto, the warrants will be issued on the first business day following the conclusion of the 10 calendar day period after the distribution of the letter required to be mailed by the Issuer to its shareholders pursuant to Section 312.05 of the NYSE Listed Company Manual (such date, the \"Closing Date\"). The warrants will be exercisable at any time after issuance and prior to the close of business on the fifth anniversary of the Closing Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Warrantholders Agreement (\"Warrantholders Agreement\"), dated April 8, 2024, between the Issuer and the holders listed on Schedule 1 thereto, the warrants will be issued on the first business day following the conclusion of the 10 calendar day period after the distribution of the letter required to be mailed by the Issuer to its shareholders pursuant to Section 312.05 of the NYSE Listed Company Manual (such date, the \"Closing Date\"). The warrants will be exercisable at any time after issuance and prior to the close of business on the fifth anniversary of the Closing Date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":123729,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":123729},"source":{"system":"sec-edgar","filing":"0000950170-24-043493","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000095017024043493/ownership.xml","form_type":"4"}},{"id":1702192,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2023-12-21T22:04:41.000Z","date":"2023-12-19","kind":"purchase","planned":false,"acquired":true,"shares":175525,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Warrants issued pursuant to the Warrantholders Agreement, dated August 4, 2023, between the Issuer and NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), and the Credit Agreement, dated August 4, 2023, between the Issuer and NEA 18 VGE."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 VGE, the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":1656789,"derivative":{"exercise_price":0.01,"exercise_date":"2023-12-20","expiration_date":"2028-08-29","underlying":"Common Stock","underlying_shares":175525},"source":{"system":"sec-edgar","filing":"0001209191-23-059457","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000120919123059457/doc4.xml","form_type":"4"}},{"id":1751388,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2023-11-02T22:54:47.000Z","date":"2023-10-31","kind":"purchase","planned":false,"acquired":true,"shares":100606,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Warrants issued pursuant to the Warrantholders Agreement, dated August 4, 2023, between the Issuer and NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), and the Credit Agreement, dated August 4, 2023, between the Issuer and NEA 18 VGE."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 VGE, the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":1481264,"derivative":{"exercise_price":0.01,"exercise_date":"2023-11-01","expiration_date":"2028-08-29","underlying":"Common Stock","underlying_shares":100606},"source":{"system":"sec-edgar","filing":"0001209191-23-054221","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000120919123054221/doc4.xml","form_type":"4"}},{"id":1777352,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2023-09-19T22:29:48.000Z","date":"2023-09-15","kind":"purchase","planned":false,"acquired":true,"shares":552263,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Warrants issued pursuant to the Warrantholders Agreement, dated August 4, 2023, between the Issuer and NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), and the Credit Agreement, dated August 4, 2023, between the Issuer and NEA 18 VGE."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 VGE, the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":1380658,"derivative":{"exercise_price":0.01,"exercise_date":"2023-09-18","expiration_date":"2028-08-29","underlying":"Common Stock","underlying_shares":552263},"source":{"system":"sec-edgar","filing":"0001209191-23-050069","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000120919123050069/doc4.xml","form_type":"4"}},{"id":1805795,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2023-08-16T12:58:53.000Z","date":"2023-08-11","kind":"purchase","planned":false,"acquired":true,"shares":828395,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Warrants to be issued pursuant to the Warrantholders Agreement and the Credit Agreement, dated August 4, 2023, between the Issuer and NEA 18 VGE."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Warrantholders Agreement (\"Warrantholders Agreement\"), dated August 4, 2023, between the Issuer and NEA 18 Venture Growth Equity L.P. (\"NEA 18 VGE\"), the warrants will be issued on the first business day following the conclusion of the 10 calendar day period after the distribution of the letter required to be mailed by the Issuer to its shareholders pursuant to Section 312.05 of the NYSE Listed Company Manual (such date, the \"Closing Date\"). The warrants will be exercisable at any time after issuance and prior to the close of business on the fifth anniversary of the Closing Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Warrantholders Agreement (\"Warrantholders Agreement\"), dated August 4, 2023, between the Issuer and NEA 18 Venture Growth Equity L.P. (\"NEA 18 VGE\"), the warrants will be issued on the first business day following the conclusion of the 10 calendar day period after the distribution of the letter required to be mailed by the Issuer to its shareholders pursuant to Section 312.05 of the NYSE Listed Company Manual (such date, the \"Closing Date\"). The warrants will be exercisable at any time after issuance and prior to the close of business on the fifth anniversary of the Closing Date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 VGE, the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":828395,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":828395},"source":{"system":"sec-edgar","filing":"0001209191-23-045955","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000120919123045955/doc4.xml","form_type":"4"}},{"id":1827050,"issuer":{"id":4900,"kind":"organization","name":"Savara Inc","symbol":"SVRA"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-07-19T23:12:32.000Z","date":"2023-07-17","kind":"purchase","planned":false,"acquired":true,"shares":333333,"price":3,"value":999999.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reports the purchase of shares in the underwritten public offering of common stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"). NEA 17 is the sole member of Growth Equity Opportunities 17, LLC (\"GEO 17\"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by GEO 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":24471264,"source":{"system":"sec-edgar","filing":"0001209191-23-042804","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1160308/000120919123042804/doc4.xml","form_type":"4"}},{"id":1854460,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-15T20:36:41.000Z","date":"2023-06-13","kind":"other","planned":false,"acquired":true,"shares":114,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 7"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Paul E. Walker and Abbey S. Walker, as Trustees of the Walker Family 2017 Trust Dated February 13, 2017 (the \"Walker Family 2017 Trust\"), received 114 shares of Common Stock of the Issuer in the distribution made by NEA Partners 16 on June 13, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The securities are held directly by the Walker Family 2017 Trust. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by the Walker Family 2017 Trust in which the Reporting Person has no pecuniary interest."}],"balance_after":114,"source":{"system":"sec-edgar","filing":"0001209191-23-037366","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000120919123037366/doc4.xml","form_type":"4"}},{"id":1854459,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-15T20:36:41.000Z","date":"2023-06-13","kind":"other","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"NEA Partners 16 made a pro rata distribution for no consideration of an aggregate of 30,000 shares of Common Stock of the Issuer to its limited partners on June 13, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 16 GP, which is the sole general partner of NEA Partners 16, the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA Partners 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-037366","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000120919123037366/doc4.xml","form_type":"4"}},{"id":1854458,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-15T20:36:41.000Z","date":"2023-06-13","kind":"other","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"NEA Partners 16 received 30,000 shares of Common Stock of the Issuer in the distribution made by NEA 16 on June 13, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 16 GP, which is the sole general partner of NEA Partners 16, the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA Partners 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001209191-23-037366","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000120919123037366/doc4.xml","form_type":"4"}},{"id":1854457,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-15T20:36:41.000Z","date":"2023-06-13","kind":"other","planned":false,"acquired":false,"shares":2000000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"New Enterprise Associates 16, L.P. (\"NEA 16\") made a pro rata distribution of 2,000,000 shares of Common Stock of the Issuer to its general partner and limited partners for no consideration on June 13, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 16 GP, LLC (\"NEA 16 GP\"), which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of NEA 16, the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":2186243,"source":{"system":"sec-edgar","filing":"0001209191-23-037366","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000120919123037366/doc4.xml","form_type":"4"}},{"id":1874292,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2023-05-30T18:32:08.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":86762,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 100% of the shares on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual Meeting of stockholders that occurs following the grant, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":86762,"derivative":{"exercise_price":4.81,"expiration_date":"2033-05-25","underlying":"Common Stock","underlying_shares":86762},"source":{"system":"sec-edgar","filing":"0001209191-23-032999","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000120919123032999/doc4.xml","form_type":"4"}},{"id":2098395,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-12-02T17:13:26.000Z","date":"2022-11-30","kind":"other","acquired":false,"shares":4294207,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Kearny Acquisition Corporation (\"Merger Sub\"), dated as of October 17, 2022, these shares of common stock, par value $0.0001 per share, of the Issuer (\"Shares\") were tendered prior to the Expiration Date (as defined in the Merger Agreement) and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for (i) $12.50 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding, plus (ii) one non-tradable contingent value right (\"CVR\") per Share, which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, [Continued on Note 2]"},{"field":"shares","element":"transactionShares","label":"F2","text":"[Continuation of Note 1] upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Parent, Merger Sub, Computershare Inc. and Computershare Trust Company, N.A."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Kearny Acquisition Corporation (\"Merger Sub\"), dated as of October 17, 2022, these shares of common stock, par value $0.0001 per share, of the Issuer (\"Shares\") were tendered prior to the Expiration Date (as defined in the Merger Agreement) and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for (i) $12.50 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding, plus (ii) one non-tradable contingent value right (\"CVR\") per Share, which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, [Continued on Note 2]"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"[Continuation of Note 1] upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Parent, Merger Sub, Computershare Inc. and Computershare Trust Company, N.A."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 16 securities in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-22-059461","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722271/000120919122059461/doc4.xml","form_type":"4"}},{"id":2134756,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Perpetual Preferred Stock","published_at":"2022-10-20T00:03:52.000Z","date":"2022-10-17","kind":"purchase","acquired":true,"shares":100000,"price":1000,"value":100000000.0,"ownership":{"direct":false,"nature":"See Note 5"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Issuer's Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") is convertible at the option of the holder (subject to the expiration or early termination of the applicable waiting period, if any, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended) into the number of shares of the Issuer's common stock (\"Common Stock\") equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 plus increases for accumulated quarterly dividends that are not paid in cash (\"compounded dividends\")) plus (ii) the accrued dividends with respect to each share of Series B Preferred Stock as of the applicable conversion date divided by (b) the conversion price as of the applicable conversion date (initially approximately $1.4169), subject to anti-dilution adjustments."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") is convertible at the option of the holder (subject to the expiration or early termination of the applicable waiting period, if any, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended) into the number of shares of the Issuer's common stock (\"Common Stock\") equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 plus increases for accumulated quarterly dividends that are not paid in cash (\"compounded dividends\")) plus (ii) the accrued dividends with respect to each share of Series B Preferred Stock as of the applicable conversion date divided by (b) the conversion price as of the applicable conversion date (initially approximately $1.4169), subject to anti-dilution adjustments."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Issuer's Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") is convertible at the option of the holder (subject to the expiration or early termination of the applicable waiting period, if any, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended) into the number of shares of the Issuer's common stock (\"Common Stock\") equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 plus increases for accumulated quarterly dividends that are not paid in cash (\"compounded dividends\")) plus (ii) the accrued dividends with respect to each share of Series B Preferred Stock as of the applicable conversion date divided by (b) the conversion price as of the applicable conversion date (initially approximately $1.4169), subject to anti-dilution adjustments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B Preferred Stock has no expiration date. At any time after the third anniversary of the original issuance date, if the closing price per share of Common Stock is greater than 287% of the then applicable conversion price (initially $4.07) for (x) at least 20 trading days in any period of 30 consecutive trading days and (y) the last trading day immediately before the Issuer provides notice of its election to convert, the Issuer may elect to convert all of the Series B Preferred Stock into the relevant number of shares of Common Stock. [Continued on Note 3]"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"[Continuation of Note 2] At any time following the fifth anniversary of the original issuance date, the Issuer may redeem all of the Series B Preferred Stock for a per share amount in cash equal to: (i) the sum of (A) the liquidation preference (reflecting increases for compounded dividends) thereof plus (B) all accrued dividends as of the applicable redemption date, multiplied by (ii) (A) 105% if the redemption occurs at any time prior to the seventh anniversary of the original issuance date and (B) 100% if the redemption occurs at any time on or after the seventh anniversary of the original issuance date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":100000,"derivative":{"underlying":"Common Stock","underlying_shares":70574720},"source":{"system":"sec-edgar","filing":"0001209191-22-054147","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000120919122054147/doc4.xml","form_type":"4"}},{"id":2134755,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Perpetual Preferred Stock","published_at":"2022-10-20T00:03:52.000Z","date":"2022-10-17","kind":"purchase","acquired":true,"shares":37700,"price":1000,"value":37700000.0,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Issuer's Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") is convertible at the option of the holder (subject to the expiration or early termination of the applicable waiting period, if any, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended) into the number of shares of the Issuer's common stock (\"Common Stock\") equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 plus increases for accumulated quarterly dividends that are not paid in cash (\"compounded dividends\")) plus (ii) the accrued dividends with respect to each share of Series B Preferred Stock as of the applicable conversion date divided by (b) the conversion price as of the applicable conversion date (initially approximately $1.4169), subject to anti-dilution adjustments."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") is convertible at the option of the holder (subject to the expiration or early termination of the applicable waiting period, if any, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended) into the number of shares of the Issuer's common stock (\"Common Stock\") equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 plus increases for accumulated quarterly dividends that are not paid in cash (\"compounded dividends\")) plus (ii) the accrued dividends with respect to each share of Series B Preferred Stock as of the applicable conversion date divided by (b) the conversion price as of the applicable conversion date (initially approximately $1.4169), subject to anti-dilution adjustments."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Issuer's Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") is convertible at the option of the holder (subject to the expiration or early termination of the applicable waiting period, if any, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended) into the number of shares of the Issuer's common stock (\"Common Stock\") equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 plus increases for accumulated quarterly dividends that are not paid in cash (\"compounded dividends\")) plus (ii) the accrued dividends with respect to each share of Series B Preferred Stock as of the applicable conversion date divided by (b) the conversion price as of the applicable conversion date (initially approximately $1.4169), subject to anti-dilution adjustments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B Preferred Stock has no expiration date. At any time after the third anniversary of the original issuance date, if the closing price per share of Common Stock is greater than 287% of the then applicable conversion price (initially $4.07) for (x) at least 20 trading days in any period of 30 consecutive trading days and (y) the last trading day immediately before the Issuer provides notice of its election to convert, the Issuer may elect to convert all of the Series B Preferred Stock into the relevant number of shares of Common Stock. [Continued on Note 3]"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"[Continuation of Note 2] At any time following the fifth anniversary of the original issuance date, the Issuer may redeem all of the Series B Preferred Stock for a per share amount in cash equal to: (i) the sum of (A) the liquidation preference (reflecting increases for compounded dividends) thereof plus (B) all accrued dividends as of the applicable redemption date, multiplied by (ii) (A) 105% if the redemption occurs at any time prior to the seventh anniversary of the original issuance date and (B) 100% if the redemption occurs at any time on or after the seventh anniversary of the original issuance date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":37700,"derivative":{"underlying":"Common Stock","underlying_shares":26606669},"source":{"system":"sec-edgar","filing":"0001209191-22-054147","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000120919122054147/doc4.xml","form_type":"4"}},{"id":2151771,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-23T16:35:16.000Z","date":"2022-09-21","kind":"purchase","acquired":true,"shares":3386400,"price":5.02,"value":16999728.0,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reports the purchase of shares in the underwritten public offering of common stock of Allakos, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 18 VG GP, LLC, which is the sole general partner of NEA Partners 18 VG, L.P. (\"NEA Partners 18 VG\"). NEA Partners 18 VG is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":3386400,"source":{"system":"sec-edgar","filing":"0001209191-22-051146","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000120919122051146/doc4.xml","form_type":"4"}},{"id":2151770,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-23T16:35:16.000Z","date":"2022-09-21","kind":"purchase","acquired":true,"shares":597600,"price":5.02,"value":2999952.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reports the purchase of shares in the underwritten public offering of common stock of Allakos, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 16 securities in which the Reporting Person has no pecuniary interest."}],"balance_after":2760860,"source":{"system":"sec-edgar","filing":"0001209191-22-051146","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000120919122051146/doc4.xml","form_type":"4"}},{"id":2252780,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-27T17:02:14.000Z","date":"2022-05-25","kind":"grant","acquired":true,"shares":99590,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest as to 100% of the shares on the earlier of (i) the one-year anniversary of the date of the grant or (ii) the date of the Issuer's next Annual Meeting of stockholders that occurs following the grant, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":99590,"derivative":{"exercise_price":2.62,"expiration_date":"2032-05-25","underlying":"Common Stock","underlying_shares":99590},"source":{"system":"sec-edgar","filing":"0001209191-22-032622","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000120919122032622/doc4.xml","form_type":"4"}},{"id":2255181,"issuer":{"id":12635,"kind":"organization","name":"GENOCEA BIOSCIENCES, INC.","symbol":"GNCA"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-26T18:32:49.000Z","date":"2022-05-25","kind":"sale","acquired":false,"shares":4445093,"price":0.0816,"value":362719.5888,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.0675 to $0.0980, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), which is the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-22-032331","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1457612/000120919122032331/doc4.xml","form_type":"4"}},{"id":2255180,"issuer":{"id":12635,"kind":"organization","name":"GENOCEA BIOSCIENCES, INC.","symbol":"GNCA"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-26T18:32:49.000Z","date":"2022-05-24","kind":"sale","acquired":false,"shares":5931843,"price":0.0654,"value":387942.5322,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.060 to\n$0.0746, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in\nthis footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), which is the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":4445093,"source":{"system":"sec-edgar","filing":"0001209191-22-032331","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1457612/000120919122032331/doc4.xml","form_type":"4"}},{"id":2297549,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants","published_at":"2022-04-13T17:29:04.000Z","date":"2022-04-11","kind":"purchase","acquired":true,"shares":3000000,"price":1.899,"value":5697000.0,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired from the Issuer on April 11, 2022 pursuant to a Securities Purchase Agreement dated April 6, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Pre-Funded Warrants are exercisable immediately and will be exercisable until exercised in full. The Pre-Funded Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the Issuer's common stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 9.99% of the Issuer's common stock outstanding immediately after giving effect to such exercise, which percentage may be increased or decreased at the holder's election upon 61 days' notice to the Issuer, not to exceed 19.99%."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Pre-Funded Warrants are exercisable immediately and will be exercisable until exercised in full. The Pre-Funded Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the Issuer's common stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 9.99% of the Issuer's common stock outstanding immediately after giving effect to such exercise, which percentage may be increased or decreased at the holder's election upon 61 days' notice to the Issuer, not to exceed 19.99%."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 18 VG GP, LLC, which is the sole general partner of NEA Partners 18 VG, L.P. (\"NEA Partners 18 VG\"). NEA Partners 18 VG is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":3000000,"derivative":{"exercise_price":0.001,"underlying":"Common Stock","underlying_shares":3000000},"source":{"system":"sec-edgar","filing":"0001209191-22-024322","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000120919122024322/doc4.xml","form_type":"4"}},{"id":2297548,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-04-13T17:29:04.000Z","date":"2022-04-11","kind":"purchase","acquired":true,"shares":948948,"price":1.9,"value":1803001.2,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired from the Issuer on April 11, 2022 pursuant to a Securities Purchase Agreement dated April 6, 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 18 VG GP, LLC, which is the sole general partner of NEA Partners 18 VG, L.P. (\"NEA Partners 18 VG\"). NEA Partners 18 VG is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":948948,"source":{"system":"sec-edgar","filing":"0001209191-22-024322","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000120919122024322/doc4.xml","form_type":"4"}},{"id":2297547,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-04-13T17:29:04.000Z","date":"2022-04-11","kind":"purchase","acquired":true,"shares":2631578,"price":1.9,"value":4999998.2,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired from the Issuer on April 11, 2022 pursuant to a Securities Purchase Agreement dated April 6, 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 16 securities in which the Reporting Person has no pecuniary interest."}],"balance_after":10421428,"source":{"system":"sec-edgar","filing":"0001209191-22-024322","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000120919122024322/doc4.xml","form_type":"4"}},{"id":2443998,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Perpetual Preferred Stock","published_at":"2022-01-05T23:02:20.000Z","date":"2022-01-03","kind":"purchase","acquired":true,"shares":125000,"price":1000,"value":125000000.0,"ownership":{"direct":false,"nature":"See Note 5"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Issuer's Series A Convertible Perpetual Preferred Stock (\"Preferred Stock\") is convertible at the option of the holder (subject to the expiration or early termination of the applicable waiting period, if any, under the HSR Act) into the number of shares of Issuer's common stock (\"Common Stock\") equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 plus increases for compounded dividends) plus (ii) the accrued dividends with respect to each share of Preferred Stock as of the applicable conversion date divided by (b) the conversion price (initially approximately $4.55) as of the applicable conversion date, subject to anti-dilution adjustments."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's Series A Convertible Perpetual Preferred Stock (\"Preferred Stock\") is convertible at the option of the holder (subject to the expiration or early termination of the applicable waiting period, if any, under the HSR Act) into the number of shares of Issuer's common stock (\"Common Stock\") equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 plus increases for compounded dividends) plus (ii) the accrued dividends with respect to each share of Preferred Stock as of the applicable conversion date divided by (b) the conversion price (initially approximately $4.55) as of the applicable conversion date, subject to anti-dilution adjustments."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Issuer's Series A Convertible Perpetual Preferred Stock (\"Preferred Stock\") is convertible at the option of the holder (subject to the expiration or early termination of the applicable waiting period, if any, under the HSR Act) into the number of shares of Issuer's common stock (\"Common Stock\") equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 plus increases for compounded dividends) plus (ii) the accrued dividends with respect to each share of Preferred Stock as of the applicable conversion date divided by (b) the conversion price (initially approximately $4.55) as of the applicable conversion date, subject to anti-dilution adjustments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Preferred Stock has no expiration date. At any time after the third anniversary of the original issuance date, if the closing price per share of Common Stock is greater than 175% of the then-applicable conversion price (initially $7.96) for (x) at least 20 in any period of 30 consecutive trading days and (y) the last trading day immediately before the Issuer provides notice of its election to convert, the Issuer may elect to convert all of the Preferred Stock into the relevant number of shares of Common Stock. [Continued on Note 3]"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"[Continuation of Note 2] At any time following the fifth anniversary of the original issuance date, the Issuer may redeem all of the Preferred Stock for a per share amount in cash equal to: (i) the sum of (A) the liquidation preference (reflecting increases for compounded dividends) thereof plus (B) all accrued dividends as of the applicable redemption date, multiplied by (ii) (A) 105% if the redemption occurs at any time prior to the seventh anniversary of the original issuance date and (B) 100% if the redemption occurs at any time on or after the seventh anniversary of the original issuance date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC (\"NEA 18 VGE GP\"), which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":125000,"derivative":{"underlying":"Common Stock","underlying_shares":27481137},"source":{"system":"sec-edgar","filing":"0001209191-22-001915","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000120919122001915/doc4.xml","form_type":"4"}},{"id":2443997,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Perpetual Preferred Stock","published_at":"2022-01-05T23:02:20.000Z","date":"2022-01-03","kind":"purchase","acquired":true,"shares":75000,"price":1000,"value":75000000.0,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Issuer's Series A Convertible Perpetual Preferred Stock (\"Preferred Stock\") is convertible at the option of the holder (subject to the expiration or early termination of the applicable waiting period, if any, under the HSR Act) into the number of shares of Issuer's common stock (\"Common Stock\") equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 plus increases for compounded dividends) plus (ii) the accrued dividends with respect to each share of Preferred Stock as of the applicable conversion date divided by (b) the conversion price (initially approximately $4.55) as of the applicable conversion date, subject to anti-dilution adjustments."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's Series A Convertible Perpetual Preferred Stock (\"Preferred Stock\") is convertible at the option of the holder (subject to the expiration or early termination of the applicable waiting period, if any, under the HSR Act) into the number of shares of Issuer's common stock (\"Common Stock\") equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 plus increases for compounded dividends) plus (ii) the accrued dividends with respect to each share of Preferred Stock as of the applicable conversion date divided by (b) the conversion price (initially approximately $4.55) as of the applicable conversion date, subject to anti-dilution adjustments."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Issuer's Series A Convertible Perpetual Preferred Stock (\"Preferred Stock\") is convertible at the option of the holder (subject to the expiration or early termination of the applicable waiting period, if any, under the HSR Act) into the number of shares of Issuer's common stock (\"Common Stock\") equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 plus increases for compounded dividends) plus (ii) the accrued dividends with respect to each share of Preferred Stock as of the applicable conversion date divided by (b) the conversion price (initially approximately $4.55) as of the applicable conversion date, subject to anti-dilution adjustments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Preferred Stock has no expiration date. At any time after the third anniversary of the original issuance date, if the closing price per share of Common Stock is greater than 175% of the then-applicable conversion price (initially $7.96) for (x) at least 20 in any period of 30 consecutive trading days and (y) the last trading day immediately before the Issuer provides notice of its election to convert, the Issuer may elect to convert all of the Preferred Stock into the relevant number of shares of Common Stock. [Continued on Note 3]"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"[Continuation of Note 2] At any time following the fifth anniversary of the original issuance date, the Issuer may redeem all of the Preferred Stock for a per share amount in cash equal to: (i) the sum of (A) the liquidation preference (reflecting increases for compounded dividends) thereof plus (B) all accrued dividends as of the applicable redemption date, multiplied by (ii) (A) 105% if the redemption occurs at any time prior to the seventh anniversary of the original issuance date and (B) 100% if the redemption occurs at any time on or after the seventh anniversary of the original issuance date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":75000,"derivative":{"underlying":"Common Stock","underlying_shares":16488682},"source":{"system":"sec-edgar","filing":"0001209191-22-001915","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000120919122001915/doc4.xml","form_type":"4"}},{"id":2458412,"issuer":{"id":115177,"kind":"organization","name":"Metacrine, Inc.","symbol":"MTCR"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-27T16:47:00.000Z","date":"2021-12-22","kind":"sale","acquired":false,"shares":170932,"price":0.9101,"value":155565.2132,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 16 securities in which the Reporting Person has no pecuniary interest."}],"balance_after":2563257,"source":{"system":"sec-edgar","filing":"0001209191-21-071274","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000120919121071274/doc4.xml","form_type":"4"}},{"id":2458411,"issuer":{"id":115177,"kind":"organization","name":"Metacrine, Inc.","symbol":"MTCR"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-27T16:47:00.000Z","date":"2021-12-22","kind":"sale","acquired":false,"shares":288768,"price":1.0018,"value":289287.7824,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 16 securities in which the Reporting Person has no pecuniary interest."}],"balance_after":2734189,"source":{"system":"sec-edgar","filing":"0001209191-21-071274","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000120919121071274/doc4.xml","form_type":"4"}},{"id":2458410,"issuer":{"id":115177,"kind":"organization","name":"Metacrine, Inc.","symbol":"MTCR"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-27T16:47:00.000Z","date":"2021-12-10","kind":"sale","acquired":false,"shares":37570,"price":1.321,"value":49629.97,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 16 securities in which the Reporting Person has no pecuniary interest."}],"balance_after":3022957,"source":{"system":"sec-edgar","filing":"0001209191-21-071274","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000120919121071274/doc4.xml","form_type":"4"}},{"id":2502279,"issuer":{"id":133265,"kind":"organization","name":"Trillium Therapeutics Inc.","symbol":"TRIL"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-19T15:34:15.000Z","date":"2021-11-17","kind":"disposition_to_issuer","acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Effective Time, each option to purchase Shares (an \"Option\") outstanding immediately prior to the Effective Time was deemed to be assigned and transferred to the Issuer in exchange for a cash payment equal to the amount by which the Consideration exceeded the per share exercise price of such Option."}],"balance_after":0,"derivative":{"exercise_price":12.03,"expiration_date":"2030-12-23","underlying":"Common Shares","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-21-065762","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000120919121065762/doc4.xml","form_type":"4"}},{"id":2502278,"issuer":{"id":133265,"kind":"organization","name":"Trillium Therapeutics Inc.","symbol":"TRIL"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant to Purchase Series II Preferred Shares","published_at":"2021-11-19T15:34:15.000Z","date":"2021-11-17","kind":"disposition_to_issuer","acquired":false,"shares":5400000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each warrant to purchase Shares (a \"Warrant\") outstanding immediately prior to the Effective Time was transferred to the Issuer for, at the holder's election: (x) a cash payment equal to the amount by which the Consideration exceeded the per share exercise price such Warrant, or (y) a cash payment equal to the amount by which the Black-Scholes value of such exceeded the per share exercise price of such Warrant."}],"balance_after":0,"derivative":{"exercise_price":0.96,"expiration_date":"2024-02-28","underlying":"Series II Non-Voting Convertible First Preferred Shares","underlying_shares":5400000},"source":{"system":"sec-edgar","filing":"0001209191-21-065762","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000120919121065762/doc4.xml","form_type":"4"}},{"id":2502277,"issuer":{"id":133265,"kind":"organization","name":"Trillium Therapeutics Inc.","symbol":"TRIL"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series II Non-Voting Convertible First Preferred Shares","published_at":"2021-11-19T15:34:15.000Z","date":"2021-11-17","kind":"disposition_to_issuer","acquired":false,"shares":6750000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On November 17, 2021, PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the \"Purchaser\") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the \"Issuer\") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the \"Plan of Arrangement\"), whereby the Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the \"Effective Time\") of the Plan of Arrangement, all common shares and preferred shares (collectively, \"Shares\") of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash (the \"Consideration\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On November 17, 2021, PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the \"Purchaser\") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the \"Issuer\") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the \"Plan of Arrangement\"), whereby the Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the \"Effective Time\") of the Plan of Arrangement, all common shares and preferred shares (collectively, \"Shares\") of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash (the \"Consideration\")."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":6750000},"source":{"system":"sec-edgar","filing":"0001209191-21-065762","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000120919121065762/doc4.xml","form_type":"4"}}],"next_cursor":"2021-11-19T15:34:15.000000Z,2502277"}